Literature DB >> 7552690

Methods for construction of adenovirus vectors.

F L Graham1, L Prevec.   

Abstract

Adenoviruses are attracting increasing attention as general purpose mammalian cell expression vectors, as recombinant vaccines, and potentially as vectors for gene therapy. Not only is the adenovirus genome relatively easy to manipulate by recombinant DNA techniques, but adenovirus vectors are relatively stable, grow to high titers, and can transduce a variety of cell types in cell culture and in vivo. Vectors can be designed that are either replication competent or replication defective and, in the latter case, are highly efficient at delivering and expressing genes in mammalian cells without resulting in cell killing. Methods are described for growing, titrating, and purifying adenoviruses, for extracting viral DNA from purified virions and from infected cells, for rescuing inserts of foreign DNA into the viral genome, and for assessing expression of inserted genes in adenovirus vectors.

Entities:  

Mesh:

Year:  1995        PMID: 7552690     DOI: 10.1007/BF02789331

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  24 in total

Review 1.  Expression of heterologous sequences in adenoviral vectors.

Authors:  K L Berkner
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  Herpes simplex virus IgG Fc receptors induced using recombinant adenovirus vectors expressing glycoproteins E and I.

Authors:  T Hanke; F L Graham; V Lulitanond; D C Johnson
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

3.  Growth of 293 cells in suspension culture.

Authors:  F L Graham
Journal:  J Gen Virol       Date:  1987-03       Impact factor: 3.891

4.  A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5.

Authors:  W J McGrory; D S Bautista; F L Graham
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

5.  Cloning of the herpes simplex virus ICP4 gene in an adenovirus vector: effects on adenovirus gene expression and replication.

Authors:  R Spessot; K Inchley; T M Hupel; S Bacchetti
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

6.  Expression of the glycoprotein of vesicular stomatitis virus by infectious adenovirus vectors.

Authors:  M Schneider; F L Graham; L Prevec
Journal:  J Gen Virol       Date:  1989-02       Impact factor: 3.891

7.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

Authors:  A J Bett; W Haddara; L Prevec; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

8.  Generation of adenovirus by transfection of plasmids.

Authors:  K L Berkner; P A Sharp
Journal:  Nucleic Acids Res       Date:  1983-09-10       Impact factor: 16.971

9.  Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells.

Authors:  N Jones; T Shenk
Journal:  Cell       Date:  1979-07       Impact factor: 41.582

10.  Covalently closed circles of human adenovirus DNA are infectious.

Authors:  F L Graham
Journal:  EMBO J       Date:  1984-12-01       Impact factor: 11.598

View more
  89 in total

1.  Frequency and stability of chromosomal integration of adenovirus vectors.

Authors:  A Harui; S Suzuki; S Kochanek; K Mitani
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression.

Authors:  L He; J Liu; I Collins; S Sanford; B O'Connell; C J Benham; D Levens
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

3.  E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors.

Authors:  M Y Hsu; F E Meier; M Nesbit; J Y Hsu; P Van Belle; D E Elder; M Herlyn
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

4.  High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach.

Authors:  B M Foxwell; S Yoshimura; J Bondeson; F M Brennan; M Feldmann
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

5.  Embryonic neurons adapt to the inhibitory proteoglycan aggrecan by increasing integrin expression.

Authors:  M L Condic; D M Snow; P C Letourneau
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

Review 6.  Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?

Authors:  M Feldmann; E Andreakos; C Smith; J Bondeson; S Yoshimura; S Kiriakidis; C Monaco; C Gasparini; S Sacre; A Lundberg; E Paleolog; N J Horwood; F M Brennan; B M J Foxwell
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 7.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

8.  Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.

Authors:  Nikolay Korokhov; Galina Mikheeva; Alexander Krendelshchikov; Natalya Belousova; Vera Simonenko; Valentina Krendelshchikova; Alexander Pereboev; Alexander Kotov; Olga Kotova; Pierre L Triozzi; Wayne A Aldrich; Joanne T Douglas; Kin-Ming Lo; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

9.  Expressed cell-penetrating peptides can induce a bystander effect, but passage through the secretory pathway reduces protein transduction activity.

Authors:  Ying Shen; William Yu; John G Hay; Harald Sauthoff
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

10.  Endogenous IL-10 regulates sepsis-induced thymic apoptosis and improves survival in septic IL-10 null mice.

Authors:  S K Tschoeke; C Oberholzer; D LaFace; B Hutchins; L L Moldawer; A Oberholzer
Journal:  Scand J Immunol       Date:  2008-10-08       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.